Relapsed/refractory patients

Elotuzumab combo granted FDA priority review

General MM,      & 1 more

The CHMP recommends daratumumab as front-line treatment

Patients eligible for transplant,      & 2 more

Galinpepimut-S granted FDA orphan drug designation